Animal Drug User Fee Act (ADUFA)
The Animal Drug User Fee Act of 2003 (ADUFA), amends the Federal Food, Drug, and Cosmetic Act (FFDCA) and authorizes FDA to collect fees for certain animal drug applications, and for the establishments, products and sponsors associated with these and previously approved animal drug applications, in support of the review of animal drugs. These additional resources support FDA’s responsibilities under the FFDCA to ensure that new animal drug products are safe and effective for animals as well as for the public with respect to animals intended for food consumption.
On August 14, 2008, President Bush signed the Animal Drug User Fee Amendments of 2008 (ADUFA). ADUFA was originally passed in 2003 and was set to expire on September 30, 2008. The new amendments extend ADUFA until 2013.
The ADUFA reauthorization maintains the FY 08 review timeframes for key submissions, in addition to enhancements to the program. The most significant of these is the “end review amendment” process. This amendment will enable the FDA to work with a drug manufacturer to make corrections to address deficiencies at the end of the review process, rather than restarting the review clock. This will improve efficiency by significantly reducing the number of submission review cycles.
In addition, this reauthorization encourages increased communications between FDA and industry, and also provides for improvements to the information technology infrastructure of animal drug review, providing a tool which enables industry to submit drug applications electronically and gives reviewers the ability to evaluate those applications online.
The reauthorization of ADUFA will generate $98 million in user fees over five years (FY 2009 – FY 2013).
For general questions regarding ADUFA, please send your inquiries to email@example.com.
Law - 2013 Reauthorization
Law - 2008 Reauthorization
FDA Announces FY 2015 Animal Drug User Fee Rates for ADUFA and AGDUFA FDA Seeking Public Input on Animal Drug User Fee Act Information Collection FDA Announces the Reauthorization of User Fees to Support Timely and Efficient Review of Animal Drugs and Generic Animal Drugs CVM Completes Work on Two Animal Drug User Fee Programs